Skip to main content
S 3629 117th Congress Senate Health Administrative law and regulatory procedures Cardiovascular and respiratory health Congressional oversight Department of Health and Human Services Drug therapy Drug trafficking and controlled substances Drug, alcohol, tobacco use Emergency medical services and trauma care Government information and archives Government studies and investigations Health care coverage and access Infectious and parasitic diseases Licensing and registrations Prescription drugs

Opioid Treatment Access Act of 2022

Introduced: February 10, 2022 Introduced by: Markey, Edward J. Democratic · Massachusetts See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 10, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 10, 2022
Introduced in Senate
 Plain-English summary Congressional Research Service

Opioid Treatment Access Act of 2022

This bill expands access to substance use disorder treatment by modifying the regulation of opioid treatment programs and narcotic drugs used for treatment, including with respect to a patient's unsupervised use of such drugs.

Specifically, the Department of Health and Human Services (HHS) must issue regulations to further increase patients' access to unsupervised use or handling of drugs for treatment. The Substance Abuse and Mental Health Services Administration (SAMHSA) must study the effects of these revisions, and HHS must, as appropriate, promulgate additional regulations based on the study's findings.

SAMHSA must also study the impact of certain exemptions from certification requirements for opioid treatment programs that were granted as part of COVID-19 response efforts, including any additional costs or savings that resulted from the exemptions.

The bill also (1) allows specified types of health care providers to prescribe (subject to certain requirements) methadone that is dispensed through pharmacies for a patient's unsupervised use, and (2) provides statutory authority for a regulation that allows registered opioid treatment programs to operate mobile medication units without separately registering the unit.

What's happening now February 10, 2022

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Democratic 1 Republican 1 Independent 1